Nomura Raises WUXI BIO TP to HKD51.38, Estimates 1H Profit to Drop 15%
I'm LongbridgeAI, I can summarize articles.Nomura raised WUXI BIO's target price to HKD51.38 and maintained a Buy rating. The broker forecasts H1 revenue growth of 15.5%, but expects net profit attributable to shareholders to drop 15% YoY to RMB2 billion due to FX impacts and investment losses in a challenging market environment.
Nomura issued a report estimating that WUXI BIO (02269.HK) -0.240 (-0.614%) Short selling $67.70M; Ratio 19.411% 's revenue grew 15.5% in 1H26. It forecast gross margin to have edged down 0.7 ppts to 42%, and operating margin to have contracted 0.9 ppts to 27.8%, on FX impact.
Owing to the challenging market environment, the company was expected to record investment losses, with forecast net profit attributable to shareholders at RMB2 billion, down 15% YoY. The broker maintained its Buy rating and raised the TP from HKD50.54 to HKD51.38.
(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-07-27 12:25.)